Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis
Meta-analysisHumans
- Design
- Meta-analysis
- Subjects
- 9 studies, 742 patients
- Dose used in the study
- Ultramicronised palmitoylethanolamide at 600 to 1,800 mg a day, or micronised palmitoylethanolamide with polydatin
- Duration
- At least 60 days
- What was measured
- Pain intensity at baseline, 30 days and 60 days
What the authors reported
This meta-analysis, covering 9 studies and 742 patients, found:
- Pain fell by 2.08 points (35.1%) in the first month of treatment, and a further 1.36 points (35.4%) between day 30 and day 60 (95% CI 0.98 to 1.74).
- Heterogeneity was very high (I² = 95%).
- Mild gastrointestinal effects were reported in three of the studies.
Limits of this study
The authors state that the included studies were uncontrolled. Without a comparison group, a fall in pain over time cannot be assigned to the treatment. The studies were small and covered different conditions, doses and formulations, some combined with polydatin. The review received no external funding.
Source
PubMed 38892586 · doi:10.3390/nu16111653
Entry checked against the abstract on PubMed, and the full text at the publisher (MDPI) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.